288 related articles for article (PubMed ID: 28495078)
1. Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease.
Arends M; Wijburg FA; Wanner C; Vaz FM; van Kuilenburg ABP; Hughes DA; Biegstraaten M; Mehta A; Hollak CEM; Langeveld M
Mol Genet Metab; 2017 Jun; 121(2):157-161. PubMed ID: 28495078
[TBL] [Abstract][Full Text] [Related]
2. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy.
van Breemen MJ; Rombach SM; Dekker N; Poorthuis BJ; Linthorst GE; Zwinderman AH; Breunig F; Wanner C; Aerts JM; Hollak CE
Biochim Biophys Acta; 2011 Jan; 1812(1):70-6. PubMed ID: 20851180
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
4. Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A).
Liao HC; Huang YH; Chen YJ; Kao SM; Lin HY; Huang CK; Liu HC; Hsu TR; Lin SP; Yang CF; Fann CS; Chiu PC; Hsieh KS; Fu YC; Ke YY; Lin CY; Tsai FJ; Wang CH; Chao MC; Yu WC; Chiang CC; Niu DM
Clin Chim Acta; 2013 Nov; 426():114-20. PubMed ID: 24055776
[TBL] [Abstract][Full Text] [Related]
5. Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease.
Smid BE; van der Tol L; Biegstraaten M; Linthorst GE; Hollak CE; Poorthuis BJ
J Med Genet; 2015 Apr; 52(4):262-8. PubMed ID: 25596309
[TBL] [Abstract][Full Text] [Related]
6. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome.
Rombach SM; Aerts JM; Poorthuis BJ; Groener JE; Donker-Koopman W; Hendriks E; Mirzaian M; Kuiper S; Wijburg FA; Hollak CE; Linthorst GE
PLoS One; 2012; 7(10):e47805. PubMed ID: 23094092
[TBL] [Abstract][Full Text] [Related]
7. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease.
Rombach SM; Dekker N; Bouwman MG; Linthorst GE; Zwinderman AH; Wijburg FA; Kuiper S; Vd Bergh Weerman MA; Groener JE; Poorthuis BJ; Hollak CE; Aerts JM
Biochim Biophys Acta; 2010 Sep; 1802(9):741-8. PubMed ID: 20471476
[TBL] [Abstract][Full Text] [Related]
8. Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients.
Smid BE; Rombach SM; Aerts JM; Kuiper S; Mirzaian M; Overkleeft HS; Poorthuis BJ; Hollak CE; Groener JE; Linthorst GE
Orphanet J Rare Dis; 2011 Oct; 6():69. PubMed ID: 22041095
[TBL] [Abstract][Full Text] [Related]
9. Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine.
Rombach SM; van den Bogaard B; de Groot E; Groener JE; Poorthuis BJ; Linthorst GE; van den Born BJ; Hollak CE; Aerts JM
Hypertension; 2012 Oct; 60(4):998-1005. PubMed ID: 22868390
[TBL] [Abstract][Full Text] [Related]
10. Amelioration of serum 8-OHdG level by enzyme replacement therapy in patients with Fabry cardiomyopathy.
Chen KH; Chou YC; Hsiao CY; Chien Y; Wang KL; Lai YH; Chang YL; Niu DM; Yu WC
Biochem Biophys Res Commun; 2017 Apr; 486(2):293-299. PubMed ID: 28300554
[TBL] [Abstract][Full Text] [Related]
11. Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY.
Mauhin W; Lidove O; Amelin D; Lamari F; Caillaud C; Mingozzi F; Dzangué-Tchoupou G; Arouche-Delaperche L; Douillard C; Dussol B; Leguy-Seguin V; D'Halluin P; Noel E; Zenone T; Matignon M; Maillot F; Ly KH; Besson G; Willems M; Labombarda F; Masseau A; Lavigne C; Froissart R; Lacombe D; Ziza JM; Hachulla E; Benveniste O
Orphanet J Rare Dis; 2018 Jul; 13(1):127. PubMed ID: 30064518
[TBL] [Abstract][Full Text] [Related]
12. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.
Arends M; Biegstraaten M; Wanner C; Sirrs S; Mehta A; Elliott PM; Oder D; Watkinson OT; Bichet DG; Khan A; Iwanochko M; Vaz FM; van Kuilenburg ABP; West ML; Hughes DA; Hollak CEM
J Med Genet; 2018 May; 55(5):351-358. PubMed ID: 29437868
[TBL] [Abstract][Full Text] [Related]
13. Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease.
Nowak A; Mechtler TP; Hornemann T; Gawinecka J; Theswet E; Hilz MJ; Kasper DC
Mol Genet Metab; 2018 Feb; 123(2):148-153. PubMed ID: 28728877
[TBL] [Abstract][Full Text] [Related]
14. Quantification of the Fabry marker lysoGb3 in human plasma by tandem mass spectrometry.
Krüger R; Tholey A; Jakoby T; Vogelsberger R; Mönnikes R; Rossmann H; Beck M; Lackner KJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Feb; 883-884():128-35. PubMed ID: 22138589
[TBL] [Abstract][Full Text] [Related]
15. Metabolic progression to clinical phenotype in classic Fabry disease.
Spada M; Kasper D; Pagliardini V; Biamino E; Giachero S; Porta F
Ital J Pediatr; 2017 Jan; 43(1):1. PubMed ID: 28049500
[TBL] [Abstract][Full Text] [Related]
16. Clinical parameters, LysoGb3, podocyturia, and kidney biopsy in children with Fabry disease: is a correlation possible?
Politei J; Alberton V; Amoreo O; Antongiovanni N; Arán MN; Barán M; Cabrera G; Di Pietrantonio S; Durand C; Fainboim A; Frabasil J; Pizarro FG; Iotti R; Liern M; Perretta F; Ripeau D; Toniolo F; Trimarchi H; Rivas DV; Wallace E; Schenone AB
Pediatr Nephrol; 2018 Nov; 33(11):2095-2101. PubMed ID: 29987457
[TBL] [Abstract][Full Text] [Related]
17. Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease.
Lenders M; Hennermann JB; Kurschat C; Rolfs A; Canaan-Kühl S; Sommer C; Üçeyler N; Kampmann C; Karabul N; Giese AK; Duning T; Stypmann J; Krämer J; Weidemann F; Brand SM; Wanner C; Brand E
Orphanet J Rare Dis; 2016 Jun; 11(1):88. PubMed ID: 27356758
[TBL] [Abstract][Full Text] [Related]
18. Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry.
Gold H; Mirzaian M; Dekker N; Joao Ferraz M; Lugtenburg J; Codée JD; van der Marel GA; Overkleeft HS; Linthorst GE; Groener JE; Aerts JM; Poorthuis BJ
Clin Chem; 2013 Mar; 59(3):547-56. PubMed ID: 23237761
[TBL] [Abstract][Full Text] [Related]
19. A simple method for quantification of plasma globotriaosylsphingosine: Utility for Fabry disease.
Talbot A; Nicholls K; Fletcher JM; Fuller M
Mol Genet Metab; 2017 Sep; 122(1-2):121-125. PubMed ID: 28847675
[TBL] [Abstract][Full Text] [Related]
20. α-Galactosidase A/lysoGb3 ratio as a potential marker for Fabry disease in females.
Baydakova GV; Ilyushkina AA; Moiseev S; Bychkov IO; Nikitina NV; Buruleva ТА; Zakharova EY
Clin Chim Acta; 2020 Feb; 501():27-32. PubMed ID: 31770509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]